Legend Biotech Secures Exclusive Global License for CAR-T Therapies Targeting DLL3.

The deal with Novartis seeks to advance Legend Biotech’s autologous CAR-T cell therapy candidate, LB2102, and other potential CAR-T cell therapies ...

November 14, 2023 | Tuesday | News
Senti Bio Collaborates with Celest Therapeutics to Advance SENTI-301A in China

– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...

November 07, 2023 | Tuesday | News
MoonLake Immunotherapeutics Reveals Breakthrough Phase 2 Results for Nanobody® Sonelokimab in Psoriatic Arthritis

First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of pote...

November 06, 2023 | Monday | News
Novogene Asia Pacific Middle East and Africa adopts Olink® Explore HT technology to accelerate multi-omics research with next generation proteomics

Novogene is a leading provider of genomic services and solutions offering extensive next generation sequencing (NGS) capacity and bioinformatics expertise....

November 06, 2023 | Monday | News
Illumina Launches Liquid Biopsy for Comprehensive Solid Tumor Genomic Profiling

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...

November 02, 2023 | Thursday | News
Aldeyra Therapeutics and AbbVie Sign Exclusive Option Agreement for Reproxalap License

Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...

November 02, 2023 | Thursday | News
Merck Expands Oncology Portfolio with Hengrui Partnership, Promises More Treatment Options for Difficult-to-Treat Cancers

Collaboration to develop, manufacture and commercialize next-generation selective PARP1 inhibitor HRS-1167, with option to develop, manufacture and comme...

October 31, 2023 | Tuesday | News
Adiso Therapeutics Reports Positive Phase 1b Results for ADS051 in Treating Moderate-to-Severe Ulcerative Colitis

ADS051 was safe and well-tolerated at all doses with no safety signal observed Clinical remission was achieved in 22% of patients after only 28 days on dr...

October 23, 2023 | Monday | News
Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics

Complements Existing Life Sciences and Mass Spectrometry Offerings, Accelerating Protein Biomarker Discovery and Providing Strong Synergy Opportuniti...

October 18, 2023 | Wednesday | News
Integrated DNA Technologies Opens New Facility for Growing Genomic Medicine Demand

Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE:DHR), ...

October 18, 2023 | Wednesday | News
Revvity and Element Biosciences Collaborate to Enhance NGS Research Workflow

“This collaboration between Revvity and Element Biosciences seeks to elevate the overall customer experience by providing compelling application-spec...

October 17, 2023 | Tuesday | News
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression f...

October 13, 2023 | Friday | News
AGC Biologics Completes pDNA and mRNA Line Expansion in Heidelberg

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the completion of the facilit...

October 13, 2023 | Friday | News
Multiply Labs Teams Up with UC San Francisco, Cytiva, Thermo Fisher, and Charles River for Robotic Cell Therapy Proof-of-Concept

Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs (including but not limited to...

October 12, 2023 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close